Question: is this a 2) strong advice, 1) weak advice 0) no advice?

However, first-line gefitinib should not be recommended for advanced non-small cell lung cancer (NSCLC) patients only based on clinical factors, due to a very small sample-size in our study.
user
This is a strong advice
assistant